ATE389017T1 - Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna) - Google Patents
Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna)Info
- Publication number
- ATE389017T1 ATE389017T1 AT04730318T AT04730318T ATE389017T1 AT E389017 T1 ATE389017 T1 AT E389017T1 AT 04730318 T AT04730318 T AT 04730318T AT 04730318 T AT04730318 T AT 04730318T AT E389017 T1 ATE389017 T1 AT E389017T1
- Authority
- AT
- Austria
- Prior art keywords
- myc
- sense
- antisense
- pna
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000860A ITMI20030860A1 (it) | 2003-04-29 | 2003-04-29 | Metodo per l'inibizione selettiva del gene n-myc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389017T1 true ATE389017T1 (de) | 2008-03-15 |
Family
ID=33398059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04730318T ATE389017T1 (de) | 2003-04-29 | 2004-04-29 | Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7947657B2 (de) |
| EP (1) | EP1618195B1 (de) |
| JP (1) | JP4719670B2 (de) |
| AT (1) | ATE389017T1 (de) |
| CA (1) | CA2522890C (de) |
| DE (1) | DE602004012404T2 (de) |
| DK (1) | DK1618195T3 (de) |
| ES (1) | ES2303636T3 (de) |
| IT (1) | ITMI20030860A1 (de) |
| PL (1) | PL1618195T3 (de) |
| PT (1) | PT1618195E (de) |
| WO (1) | WO2004096826A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014289A1 (en) | 2004-04-20 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| JP5108530B2 (ja) | 2005-12-26 | 2012-12-26 | 独立行政法人理化学研究所 | ＡＲＩＤ３ｂを標的とした神経芽腫の治療剤 |
| US20070281900A1 (en) * | 2006-05-05 | 2007-12-06 | Nastech Pharmaceutical Company Inc. | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY |
| ITMI20120275A1 (it) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
| US11827884B2 (en) | 2017-05-15 | 2023-11-28 | University Of Florida Research Foundation, Incorporated | Core master regulators of glioblastoma stem cells |
| WO2020246584A1 (ja) * | 2019-06-06 | 2020-12-10 | デンカ株式会社 | ペプチド核酸を基盤としたアジュバント |
-
2003
- 2003-04-29 IT IT000860A patent/ITMI20030860A1/it unknown
-
2004
- 2004-04-29 CA CA2522890A patent/CA2522890C/en not_active Expired - Lifetime
- 2004-04-29 AT AT04730318T patent/ATE389017T1/de active
- 2004-04-29 US US10/554,291 patent/US7947657B2/en active Active
- 2004-04-29 WO PCT/IB2004/001297 patent/WO2004096826A2/en active IP Right Grant
- 2004-04-29 JP JP2006506541A patent/JP4719670B2/ja not_active Expired - Lifetime
- 2004-04-29 PT PT04730318T patent/PT1618195E/pt unknown
- 2004-04-29 EP EP04730318A patent/EP1618195B1/de not_active Expired - Lifetime
- 2004-04-29 DK DK04730318T patent/DK1618195T3/da active
- 2004-04-29 DE DE602004012404T patent/DE602004012404T2/de not_active Expired - Lifetime
- 2004-04-29 PL PL04730318T patent/PL1618195T3/pl unknown
- 2004-04-29 ES ES04730318T patent/ES2303636T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PL1618195T3 (pl) | 2008-09-30 |
| PT1618195E (pt) | 2008-06-24 |
| JP4719670B2 (ja) | 2011-07-06 |
| US7947657B2 (en) | 2011-05-24 |
| CA2522890C (en) | 2013-07-02 |
| WO2004096826A2 (en) | 2004-11-11 |
| ITMI20030860A1 (it) | 2004-10-30 |
| DK1618195T3 (da) | 2008-07-07 |
| CA2522890A1 (en) | 2004-11-11 |
| US20070020632A1 (en) | 2007-01-25 |
| DE602004012404T2 (de) | 2009-03-26 |
| WO2004096826A3 (en) | 2005-05-26 |
| EP1618195A2 (de) | 2006-01-25 |
| ES2303636T3 (es) | 2008-08-16 |
| EP1618195B1 (de) | 2008-03-12 |
| DE602004012404D1 (de) | 2008-04-24 |
| JP2006525010A (ja) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE498685T1 (de) | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon | |
| DE60129799D1 (de) | Verfahren zur steigerung des haarwuchses durch wnt polypeptid | |
| DE602005007373D1 (de) | IDENTIFIKATION UND VERWENDUNG VON miRNAs ZUR DIFFERENZIERUNG MYELOGENER LEUKÄMIEZELLEN | |
| ATE507838T1 (de) | Verwendung von dipeptidylpeptidase iv und aminopeptidase-n inhibitoren zur behandlung von ischämie-induzierter neurodegeneration | |
| WO2002006316A3 (en) | Alpha-msh related compounds and methods of use | |
| MX2008014100A (es) | Compuestos y metodos para modular la expresion de pcsk9. | |
| WO2005112981A3 (en) | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells | |
| SG170819A1 (en) | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith | |
| DE60140200D1 (de) | Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung | |
| HUP0202794A2 (en) | Oligonucleotides for inhibiting the expression of human eg5 | |
| ATE389017T1 (de) | Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna) | |
| ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
| MXPA05006034A (es) | Proteina de duplicacion. | |
| TN2011000459A1 (en) | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases | |
| WO2006066154A3 (en) | Casein kinase 2 antisense therapy | |
| CY1108552T1 (el) | Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash) | |
| EA200700346A1 (ru) | Бактериофаг- и профаг-специфические протеины в генной терапии рака | |
| WO2005030225A3 (en) | Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers | |
| WO2005117974A3 (en) | Cancer treatment method by inhibiting mage gene expression or function | |
| TNSN06147A1 (en) | Use of cathepsin k inhibitors for treating of severe bone loss diseases | |
| DE60333747D1 (de) | Dna-enzym zur hemmung von plasminogenaktivator-inhibitor-1 | |
| WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS | |
| JP2006515988A (ja) | 非翻訳小ＲＮＡ（ｓｍａｌｌ，ｎｏｎ−ｔｒａｎｓｌａｔａｂｌｅＲＮＡ）による翻訳調節 | |
| WO2004012654A3 (en) | Oligonucleotides for treating proliferative disorders | |
| DE50015171D1 (de) | Rna polymerase i transkriptionsfaktor tif-ia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1618195 Country of ref document: EP |